The bill, which aims to expand patient access to diagnostic radiopharmaceuticals, mirrors companion legislation already introduced in the U.S. House of Representatives, according to the organization. It addresses structural issues in packaging methods used in the Medicare outpatient setting by directing the Department of Health and Human Services (HHS) to pay separately for all diagnostic radiopharmaceuticals with a cost threshold per day of $500, the MITA said.
If passed, this bill would give patients more access to diagnostic radiopharmaceuticals that can better detect conditions such as heart disease, Alzheimer's disease, Parkinson's disease, breast cancer, prostate cancer, and neuroendocrine tumors, the MITA said. The organization also said the bill would help providers better manage costs while delivering more targeted and cost-efficient care.
Copyright © 2021 AuntMinnie.com